Molecure S.A. Logo

Molecure S.A.

Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.

MOC | WAR

Overview

Corporate Details

ISIN(s):
PLONCTH00011
LEI:
2594003L11V38ZCVKZ09
Country:
Poland
Address:
Warszawa Żwirki i Wigury 101, 02-089 Warszawa
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Molecure S.A. is a clinical-stage biotechnology company that discovers and develops first-in-class small molecule drugs. The company focuses on treating diseases with high unmet medical needs, primarily in oncology and inflammatory and fibrotic conditions. Leveraging its in-house medicinal chemistry and biology capabilities, Molecure targets novel and unexplored protein and mRNA targets through its proprietary discovery platform. Its business model involves advancing a diverse pipeline of drug candidates to the clinical stage before engaging in licensing agreements for late-stage development and commercialization. The company was formerly known as OncoArendi, changing its name in March 2022.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-27 07:11
Quarterly Report
Skonsolidowany raport Grupy Kapitałowej za III kwartał 2025 roku
Polish 2.6 MB
2025-10-22 19:50
Report Publication Announcement
Zmiana terminu publikacji raportu za III kwartał 2025 roku. - Content (PL)
Polish 917 bytes
2025-10-21 16:00
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym…
Polish 2.0 KB
2025-10-21 15:46
Post-Annual General Meeting Information
Treść powziętych uchwał
Polish 229.8 KB
2025-10-21 15:46
Post-Annual General Meeting Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie w dniu 21 paździer…
Polish 686 bytes
2025-09-30 07:56
Audit Report / Information
Raport z przeglądu SSF 30.06.2025
Polish 236.4 KB
2025-09-30 07:56
Audit Report / Information
Raport z przeglądu JSF 30.06.2025
Polish 233.4 KB
2025-09-30 07:56
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności Molecure S.A. 30.06.2025
Polish 1.5 MB
2025-09-30 07:56
Interim Report
Skonsolidowane Sprawozdanie Finansowe Molecure S.A. 30.06.2025
Polish 1.1 MB
2025-09-30 07:56
Interim Report
Jednostkowe Sprawozdanie Finansowe Molecure S.A. 30.06.2025
Polish 1.2 MB
2025-09-26 17:16
Regulatory News Service
Informacja o pozytywnej ocenie wniosku Spółki w ramach ścieżki "SMART" - Projek…
Polish 2.5 KB
2025-09-23 15:18
Pre-Annual General Meeting Information
Zaktualizowane projekty uchwał
Polish 225.0 KB
2025-09-23 15:18
Pre-Annual General Meeting Information
Aktualizacja Zarządu dotycząca projektu Uchwały Nadzwyczajnego Walnego Zgromadz…
Polish 4.9 KB
2025-09-22 20:37
Pre-Annual General Meeting Information
Załącznik - Projekty uchwał
Polish 227.6 KB
2025-09-22 20:37
Pre-Annual General Meeting Information
Projekty uchwał Nadzwyczajnego Walnego Zgromadzenia - Content (PL)
Polish 469 bytes

Automate Your Workflow. Get a real-time feed of all Molecure S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecure S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecure S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Predictive Oncology Inc. Logo
AI platform uses a vast tumor biobank to predict drug response and accelerate oncology discovery.
United States of America
POAI
Prime Medicine, Inc. Logo
Developing 'search and replace' gene editing therapies to treat genetic disorders.
United States of America
PRME
ProPhase Labs, Inc. Logo
Genomics, diagnostics, contract manufacturing, and OTC health & wellness solutions provider.
United States of America
PRPH
PROTHENA CORP PUBLIC LTD CO Logo
Advancing antibody-based therapies for neurodegenerative and rare amyloid diseases.
United States of America
PRTA
Psomagen, Inc. Logo
A CRO providing multiomics services & data analysis for academic, biotech, and pharma researchers.
United States of America
950200
Public Policy Holding Company, Inc. Logo
Advisory group providing public policy, government relations, and strategic communications services.
United States of America
PPHC.L
Purple Biotech Ltd. Logo
Developing cancer therapies to overcome tumor immune evasion and drug resistance.
Israel
PPBT
Qualigen Therapeutics, Inc. Logo
A clinical-stage company developing innovative treatments for rare cancers in adults and children.
United States of America
QLGN
QUIA PHARMA AB Logo
Develops biobetters by enhancing approved drugs with a patented drug delivery platform.
Sweden
QUIA
QUINSTREET, INC Logo
AI-driven marketplaces connecting consumers to brands in finance & home services on a pay-per-result basis.
United States of America
QNST

Talk to a Data Expert

Have a question? We'll get back to you promptly.